Literature DB >> 17935158

Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.

Natalia D Tararova1, Natalya Narizhneva, Vadim Krivokrisenko, Andrei V Gudkov, Katerina V Gurova.   

Abstract

BACKGROUND: The precise role of androgen receptor (AR) in the normal development of prostate and the progression of prostate cancer (CaP) remains controversial. While AR expression and activity is associated with growth arrest and differentiation of normal prostate cells, it is maintained in CaP cells that are characterized by continued proliferation. Our objective was to determine the importance of AR signaling for survival and growth of CaP cells, particularly those with a hormone-refractory phenotype.
METHOD: AR expression was modulated in androgen-sensitive (AS) and androgen-insensitive (AI) CaP cells using RNAi and cDNA transduction. Resulting changes in AR transcriptional activity and cell growth were quantified.
RESULTS: Interference with AR expression in both AS and AI CaP cells by shRNA transduction demonstrated a direct correlation between residual AR expression and cell viability. CaP cells lacking AR expression undergo apoptosis several days after AR down-regulation. This delayed response suggests that AR regulates apoptosis likely through an indirect mechanism. Overexpression of AR or hyper-stimulation of AR with high levels of androgen was also poorly tolerated by CaP cells. Cells with elevated AR had a growth disadvantage due to G1 cell cycle arrest and induction of p21 and GADD45 expression.
CONCLUSIONS: CaP cells expressing endogenous AR are sensitive to both increases and decreases in AR expression levels and activity. AR in CaP cells is delicately regulated to provide a balance between cell death and continued proliferation. Thus, both approaches, inhibition and over-stimulation of AR activity, may have therapeutic value for treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935158      PMCID: PMC2914504          DOI: 10.1002/pros.20662

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  38 in total

Review 1.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Authors:  Ivan V Litvinov; Angelo M De Marzo; John T Isaacs
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

Review 2.  Hormone-refractory prostate cancer: a shifting paradigm in treatment.

Authors:  Eva Gallagher; Roxanna Gapstur
Journal:  Clin J Oncol Nurs       Date:  2006-04       Impact factor: 1.027

3.  Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor.

Authors:  Ivan V Litvinov; Lizamma Antony; John T Isaacs
Journal:  Prostate       Date:  2004-12-01       Impact factor: 4.104

4.  Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.

Authors:  H C Wu; J T Hsieh; M E Gleave; N M Brown; S Pathak; L W Chung
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

5.  Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).

Authors:  Wei-Jen Chen; Chun-Yun Chang; Jen-Kun Lin
Journal:  Biochem Pharmacol       Date:  2003-06-01       Impact factor: 5.858

Review 6.  Apoptosis in prostate cancer: progressive and therapeutic implications (Review).

Authors:  Gangduo Wang; Eddie Reed; Qingdi Q Li
Journal:  Int J Mol Med       Date:  2004-07       Impact factor: 4.101

7.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Authors:  A Hobisch; I E Eder; T Putz; W Horninger; G Bartsch; H Klocker; Z Culig
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

Review 8.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.

Authors:  S R Denmeade; X S Lin; J T Isaacs
Journal:  Prostate       Date:  1996-04       Impact factor: 4.104

9.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Authors:  M A Wainstein; F He; D Robinson; H J Kung; S Schwartz; J M Giaconia; N L Edgehouse; T P Pretlow; D R Bodner; E D Kursh
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

10.  Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival.

Authors:  Qing Yang; Kar-Ming Fung; Wanda V Day; Bradley P Kropp; Hsueh-Kung Lin
Journal:  Cancer Cell Int       Date:  2005-04-06       Impact factor: 5.722

View more
  22 in total

1.  Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.

Authors:  Anh Thu Bui; Meng-Er Huang; Maryline Havard; Fanny Laurent-Tchenio; François Dautry; Thierry Tchenio
Journal:  Cell Cycle       Date:  2017-04-20       Impact factor: 4.534

2.  ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.

Authors:  Daria Fleyshman; Peter Cheney; Anda Ströse; Shaila Mudambi; Alfiya Safina; Mairead Commane; Andrei Purmal; Kelsey Morgan; Nicholas J Wang; Joe Gray; Paul T Spellman; Natalia Issaeva; Katerina Gurova
Journal:  Cell Cycle       Date:  2015-12-22       Impact factor: 4.534

3.  CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Authors:  Vicki Gordon; Shriti Bhadel; Winfried Wunderlich; JoAnn Zhang; Scott B Ficarro; Sahana A Mollah; Jeffrey Shabanowitz; Donald F Hunt; Ioannis Xenarios; William C Hahn; Mark Conaway; Michael F Carey; Daniel Gioeli
Journal:  Mol Endocrinol       Date:  2010-10-27

4.  The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.

Authors:  Laura E Lamb; Jelani C Zarif; Cindy K Miranti
Journal:  Cancer Res       Date:  2011-02-10       Impact factor: 12.701

5.  Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

6.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28

Review 7.  Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2012-10-18       Impact factor: 9.261

8.  Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Authors:  Natalia V Narizhneva; Natalia D Tararova; Petro Ryabokon; Inna Shyshynova; Anatoly Prokvolit; Pavel G Komarov; Andrei A Purmal; Andrei V Gudkov; Katerina V Gurova
Journal:  Cell Cycle       Date:  2009-12-13       Impact factor: 4.534

9.  Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?

Authors:  Ludwig Rinnab; Stefanie V Schütz; Jeannine Diesch; Evi Schmid; Rainer Küfer; Richard E Hautmann; Klaus-Dieter Spindler; Marcus V Cronauer
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

10.  Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels.

Authors:  Qin Wei; Robert Galbenus; Ashraf Raza; Ronald L Cerny; Melanie A Simpson
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.